LGND - Ligand Pharmaceuticals Incorporated

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/201512/31/2014
Total Revenue141,102108,97371,91464,538
Cost of Revenue32,25326,79216,81218,883
Gross Profit108,84982,18155,10245,655
Operating Expenses
Research Development----
Selling General and Administrative28,65327,65325,39822,570
Non Recurring----
Others----
Total Operating Expenses73,02665,08844,58543,828
Operating Income or Loss68,07643,88527,32920,710
Income from Continuing Operations
Total Other Income/Expenses Net-10,845-35,9258,000-9,408
Earnings Before Interest and Taxes68,07643,88527,32920,710
Interest Expense-11,400-12,178-11,802-4,860
Income Before Tax57,2317,96035,32911,302
Income Tax Expense44,67510,327-192,115410
Minority Interest----1,910
Net Income From Continuing Ops12,556-2,367227,44410,892
Non-recurring Events
Discontinued Operations-731731731
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income12,556-1,636229,82412,024
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares12,556-1,636229,82412,024